Literature DB >> 24092743

Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy.

Jianming Jiang1, Hiroko Wakimoto, J G Seidman, Christine E Seidman.   

Abstract

Dominant mutations in sarcomere proteins such as the myosin heavy chains (MHC) are the leading genetic causes of human hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy. We found that expression of the HCM-causing cardiac MHC gene (Myh6) R403Q mutation in mice can be selectively silenced by an RNA interference (RNAi) cassette delivered by an adeno-associated virus vector. RNAi-transduced MHC(403/+) mice developed neither hypertrophy nor myocardial fibrosis, the pathologic manifestations of HCM, for at least 6 months. Because inhibition of HCM was achieved by only a 25% reduction in the levels of the mutant transcripts, we suggest that the variable clinical phenotype in HCM patients reflects allele-specific expression and that partial silencing of mutant transcripts may have therapeutic benefit.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24092743      PMCID: PMC4100553          DOI: 10.1126/science.1236921

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  27 in total

Review 1.  Allele-specific RNA interference for neurological disease.

Authors:  E Rodriguez-Lebron; H L Paulson
Journal:  Gene Ther       Date:  2006-03       Impact factor: 5.250

Review 2.  New recombinant serotypes of AAV vectors.

Authors:  Guangping Gao; Luk H Vandenberghe; James M Wilson
Journal:  Curr Gene Ther       Date:  2005-06       Impact factor: 4.391

3.  A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation.

Authors:  A A Geisterfer-Lowrance; S Kass; G Tanigawa; H P Vosberg; W McKenna; C E Seidman; J G Seidman
Journal:  Cell       Date:  1990-09-07       Impact factor: 41.582

Review 4.  Hypertrophic cardiomyopathy.

Authors:  Barry J Maron; Martin S Maron
Journal:  Lancet       Date:  2012-08-06       Impact factor: 79.321

5.  An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy.

Authors:  D Fatkin; B K McConnell; J O Mudd; C Semsarian; I G Moskowitz; F J Schoen; M Giewat; C E Seidman; J G Seidman
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

Review 6.  Hypertrophic cardiomyopathy in 2012.

Authors:  Carolyn Y Ho
Journal:  Circulation       Date:  2012-03-20       Impact factor: 29.690

7.  Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β.

Authors:  Polakit Teekakirikul; Seda Eminaga; Okan Toka; Ronny Alcalai; Libin Wang; Hiroko Wakimoto; Matthew Nayor; Tetsuo Konno; Joshua M Gorham; Cordula M Wolf; Jae B Kim; Joachim P Schmitt; Jefferey D Molkentin; Russell A Norris; Andrew M Tager; Stanley R Hoffman; Roger R Markwald; Christine E Seidman; Jonathan G Seidman
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

8.  Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy.

Authors:  M J Tyska; E Hayes; M Giewat; C E Seidman; J G Seidman; D M Warshaw
Journal:  Circ Res       Date:  2000-04-14       Impact factor: 17.367

9.  Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy.

Authors:  Jae Bum Kim; Gregory J Porreca; Lei Song; Steven C Greenway; Joshua M Gorham; George M Church; Christine E Seidman; J G Seidman
Journal:  Science       Date:  2007-06-08       Impact factor: 47.728

10.  Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution.

Authors:  K-M R Prasad; Y Xu; Z Yang; S T Acton; B A French
Journal:  Gene Ther       Date:  2010-08-12       Impact factor: 5.250

View more
  74 in total

1.  Gene therapy for inherited arrhythmias.

Authors:  Vassilios J Bezzerides; Maksymilian Prondzynski; Lucie Carrier; William T Pu
Journal:  Cardiovasc Res       Date:  2020-07-15       Impact factor: 10.787

2.  Cardiac myosin binding protein C regulates postnatal myocyte cytokinesis.

Authors:  Jianming Jiang; Patrick G Burgon; Hiroko Wakimoto; Kenji Onoue; Joshua M Gorham; Caitlin C O'Meara; Gregory Fomovsky; Bradley K McConnell; Richard T Lee; J G Seidman; Christine E Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-07       Impact factor: 11.205

3.  Decade in review--cardiomyopathies: Cardiomyopathy on the move.

Authors:  Magdi H Yacoub
Journal:  Nat Rev Cardiol       Date:  2014-09-30       Impact factor: 32.419

Review 4.  Genetics of paediatric cardiomyopathies.

Authors:  Stephanie M Ware
Journal:  Curr Opin Pediatr       Date:  2017-10       Impact factor: 2.856

Review 5.  Research priorities in sarcomeric cardiomyopathies.

Authors:  Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier
Journal:  Cardiovasc Res       Date:  2015-01-28       Impact factor: 10.787

Review 6.  Cell biology of sarcomeric protein engineering: disease modeling and therapeutic potential.

Authors:  Brian R Thompson; Joseph M Metzger
Journal:  Anat Rec (Hoboken)       Date:  2014-09       Impact factor: 2.064

7.  Preparation of rAAV9 to Overexpress or Knockdown Genes in Mouse Hearts.

Authors:  Jian Ding; Zhi-Qiang Lin; Jian-Ming Jiang; Christine E Seidman; Jonathan G Seidman; William T Pu; Da-Zhi Wang
Journal:  J Vis Exp       Date:  2016-12-17       Impact factor: 1.355

Review 8.  A roadmap to investigate the genetic basis of bicuspid aortic valve and its complications: insights from the International BAVCon (Bicuspid Aortic Valve Consortium).

Authors:  Siddharth K Prakash; Yohan Bossé; Jochen D Muehlschlegel; Hector I Michelena; Giuseppe Limongelli; Alessandro Della Corte; Francesca R Pluchinotta; Maria Giovanna Russo; Artur Evangelista; D Woodrow Benson; Simon C Body; Dianna M Milewicz
Journal:  J Am Coll Cardiol       Date:  2014-08-26       Impact factor: 24.094

Review 9.  Genome editing in cardiovascular diseases.

Authors:  Alanna Strong; Kiran Musunuru
Journal:  Nat Rev Cardiol       Date:  2016-09-09       Impact factor: 32.419

Review 10.  MYBPC3's alternate ending: consequences and therapeutic implications of a highly prevalent 25 bp deletion mutation.

Authors:  Diederik W D Kuster; Sakthivel Sadayappan
Journal:  Pflugers Arch       Date:  2013-12-11       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.